A daily GLP-1 pill could be an effective and simpler replacement for injectable weight-loss medications, according to a recent study published in The Lancet. The new drug, orforglipron, helps adults with obesity and type 2 diabetes significantly reduce body weight and blood sugar levels. Orforglipron is the first oral non-hormonal GLP-1 receptor agonist: it stimulates insulin production, reduces glucagon secretion, and suppresses appetite. Taken once daily, it does not require refrigeration and is not associated with injection discomfort – a key advantage over current GLP-1 therapies.
The study involved 1,613 adults from 10 countries. Over 72 weeks, participants receiving 36 milligrams of the drug lost an average of 10.5% of body weight, while the placebo group only lost 2.2%. Improvements were also seen in glycemic markers, and side effects were moderate and comparable to injectable analogs. According to researchers, orforglipron is expected to enter the market in 2026 and become a much more accessible alternative to injectable GLP-1 drugs.
Deixe um comentário